Risk prediction of hepatocellular carcinoma in patients with cirrhosis: The ADRESS-HCC risk model

Publisher： Blackwell Publishing

E-ISSN： 1097-0142|120|22|3485-3493

ISSN： 0008-543X

Source： Cancer, Vol.120, Iss.22, 2014-11, pp. : 3485-3493

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Transcutaneous Treatments of Hepatocellular Carcinoma in Patients with Cirrhosis: Present Status and Future Developments

By  

Current Pharmaceutical Design, Vol. 13, Iss. 32, 2007-11 ,pp. : 3274-3278

Bentham Science Publishers

Access to resources Recommend Favorite

Tumoural Expression of Connective Tissue Growth Factor (CTGF) Impacts on Survival in Patients Diagnosed with Hepatocellular Carcinoma (HCC)

By  

Current Cancer Drug Targets, Vol. 15, Iss. 5, 2015-01 ,pp. : 435-444

Bentham Science Publishers

Access to resources Recommend Favorite

Glutathione for Hepatotoxicity in Patients with Liver Cirrhosis and Advanced Hepatocellular Carcinoma Receiving Hepatic Arterial Infusion Chemotherapy

By  

Clinical Cancer Drugs, Vol. 2, Iss. 1, 2015-05 ,pp. : 54-60

Bentham Science Publishers

Access to resources Recommend Favorite

The Importance of Lamivudine Therapy in Liver Cirrhosis Patients Related HBV with Advanced Hepatocellular Carcinoma Receiving Hepatic Arterial Infusion Chemotherapy

By  

Clinical Cancer Drugs, Vol. 2, Iss. 2, 2015-10 ,pp. : 112-118

Bentham Science Publishers

Access to resources Recommend Favorite

Glutathione for Hepatotoxicity in Patients with Liver Cirrhosis and Advanced Hepatocellular Carcinoma Receiving Hepatic Arterial Infusion Chemotherapy

By  

Clinical Cancer Drugs, Vol. 2, Iss. 1, 2015-05 ,pp. : 54-60

Bentham Science Publishers

Access to resources Recommend Favorite